Lianyungang, China

Xiayun Chang

This inventor holds 1 USPTO granted patent. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiayun Chang. Retrieved from https://idiyas.com/inventor/xiayun-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiayun Chang: Innovator in Pharmaceutical Chemistry

Introduction

Xiayun Chang is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical applications. His work focuses on addressing critical health issues through the creation of effective pharmaceutical agents.

Latest Patents

Xiayun Chang holds a patent for a furo[3,4-b]pyrrole-containing BTK inhibitor. This invention pertains to a compound that has potential applications in treating BTK-related diseases. The patent details a preparation method for the compound, its pharmacologically acceptable salts, and pharmaceutical compositions that incorporate this innovative compound.

Career Highlights

Chang is associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the pharmaceutical industry, contributing to the development of new therapeutic options.

Collaborations

He collaborates with esteemed colleagues such as Yinsheng Zhang and Hongjiang Xu, enhancing the scope and impact of his research initiatives.

Conclusion

Xiayun Chang's contributions to pharmaceutical chemistry exemplify the importance of innovation in developing new treatments for diseases. His work not only advances scientific knowledge but also holds promise for improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…